Significant Contract Modifications ($10M+) — January 28, 2026

DHS/CBP obligated $629M to Barnard ($369M) and Spencer ($260M) for RGV-1 barriers, signaling renewed infrastructure push despite 2026 award dates.

$1.35B HHS obligation to Seqirus (options to $2.21B) with $442M outlayed underscores 20+ year federal commitment to U.S. biomanufacturing.

$2.1B+ across CACI ($921M GSA, $215M DHS), Peraton ($219M IRS), Oracle ($300M VA), Deloitte ($143M GSA) for systems design/data centers through 2026-2030.

NASA awards to GE ($199M EAP systems) and SwRI ($68M Lucy mission, options to $171M) highlight sustained funding for aviation/space tech to 2026-2034.

Low/no outlays in 10 contracts (53%), e.g., Inter-Con ($0/$530M), Barnard/Spencer ($0/$629M), signaling potential funding delays or billing issues.

Firm fixed price in 9 contracts ($1.7B+ value) exposes primes to overruns over long periods (e.g., Honeywell to 2034, Peraton to 2030).

Future-dated awards (Barnard/Spencer 2026-01-27) amid policy shifts introduce execution uncertainty for border projects.

$1.2B+ unexercised options (e.g., Seqirus $861M, Raytheon $322M to $400M, SwRI $103M) offer 20-100% upside on base obligations.

Extensions to 2028-2034 in 8 contracts (e.g., Seqirus, Honeywell, Peraton) align with federal modernization/biomanufacturing priorities.

High outlay progress in mature contracts (e.g., Hanford $403M/$475M, Peraton $217M/$219M) indicates low-risk revenue ramps.

$629M DHS obligations for RGV-1 wall/barriers to private constructors signal policy-driven construction spend despite future dates.

Over $2B in IT/data/EHR awards (CACI, Oracle, Peraton, Deloitte) through 2030 emphasize sustainment over new builds.

Seqirus ($1.35B+ vaccines), GE/SwRI (NASA R&D to 2034) reflect multi-decade federal bets on health/security tech.

{"entity"=>"Barnard Construction & Spencer Construction", "reason"=>"$629M border wall obligations with 2026 starts and $0 outlayed represent 10% of period value at policy crossroads.", "trigger"=>"DHS funding release or cancellation notices"}

{"entity"=>"Seqirus Inc", "reason"=>"Largest at $1.35B (22% of total) with $861M options and 2034 potential in biomanufacturing.", "trigger"=>"option exercises or HHS BARDA budget hikes"}

{"entity"=>"CACI International subsidiaries", "reason"=>"$1.14B across GSA/DHS IT wins with strong outlays signal scaled federal exposure.", "trigger"=>"2026 GSA recompetes"}